Natures Sunshine Products (NATR) reported $480M in revenue for fiscal 2025, +5.7% year on year. That ranks #2241 by revenue among 2853 SEC filers and #220 in Healthcare. Net income was $19.5M, a net margin of 4.1%. Revenue has grown 3.9% a year on average since 2016 ($341M then). The fiscal 2025 balance sheet shows $261M in total assets, $93.9M in cash and $0 in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $480M | +5.7% | FY20252025-12-31 |
| Gross profitGrossProfit | $348M | +7.1% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $24.7M | +23.1% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $19.5M | +153.7% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $35.3M | +39.6% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $6.5M | −40.9% | FY20252025-12-31 |
| Total assetsAssets | $261M | +8.4% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest | $162M | +0.3% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $93.9M | +10.9% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $0 | $0 | FY20232023-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $123M | $5.1M | Open → |
| Q2 20262026-06-30 | $117M | $3.5M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Natures Sunshine Products Inc
- Ticker
- NATR
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0000275053
Filings
- 10-QAug 6, 2026Open filing →
- 10-QMay 7, 2026Open filing →
- 10-KMar 10, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Ascend WellnessAAWH | $501M | −$118M |
| Travere TherapeuticsTVTX | $491M | −$25.5M |
| Porch GroupPRCH | $482M | −$3.4M |
| Natures Sunshine ProductsNATR | $480M | $19.5M |
| Zai LabZLAB | $460M | −$176M |
| AccurayARAY | $459M | −$1.6M |
| Tarsus PharmaceuticalsTARS | $451M | −$66.0M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Natures Sunshine Products — Key figures |url=https://companiesranked.com/en/company/natures-sunshine-products |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Natures Sunshine Products — Key figures. CompaniesRanked. https://companiesranked.com/en/company/natures-sunshine-productsBibTeX
@misc{companiesranked-en-company-natures-sunshine-products-2026,
author = {{CompaniesRanked}},
title = {{Natures Sunshine Products — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/natures-sunshine-products}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001628280-26-016540 · March 10, 2026
{{cite web |title=Natures Sunshine Products — Key figures — 10-K (0001628280-26-016540) |url=https://www.sec.gov/Archives/edgar/data/275053/000162828026016540/natr-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-10}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.